| Lactobacillus-related strains |
Some clinical studies report modest reductions in selected inflammatory markers, but results differ by strain, population, and study design. |
May support intestinal barrier function, digestive comfort, and microbiome balance. |
Low to moderate |
Benefits cannot be generalized across the entire group; effects are strain-specific and may be temporary. |
| Bifidobacterium-related strains |
Research suggests possible improvements in gut barrier indicators and selected inflammatory biomarkers, particularly in some gastrointestinal conditions. |
May help regulate gut function and contribute to a healthier microbial environment. |
Low to moderate |
Clinical outcomes are inconsistent, and biomarker changes do not always translate into meaningful symptom relief. |
| Multi-strain probiotic combinations |
Some trials show improvements in inflammatory markers or disease activity, while other trials find no significant advantage over control groups. |
May provide broader microbial activity when complementary strains are combined. |
Low to moderate |
Formulations are not interchangeable; the number of strains does not automatically predict effectiveness. |
| Saccharomyces boulardii |
Evidence is stronger for selected diarrhea-related conditions than for reducing systemic inflammation. |
May help maintain intestinal function during certain antibiotic-associated or infectious diarrhea episodes. |
Moderate for selected uses |
Not established as a general anti-inflammatory treatment; it may be unsuitable for severely immunocompromised people or those with central venous catheters. |
| Probiotic foods with live cultures |
Fermented foods may be associated with improved microbial diversity and lower inflammatory signals in some dietary studies, but direct causation is not established. |
Can provide live microorganisms along with protein, calcium, or other nutrients, depending on the food. |
Limited to moderate |
Microbial content varies, and many fermented foods are not standardized or clinically tested for specific inflammatory outcomes. |
| Probiotics for inflammatory bowel disease |
Evidence is mixed. Some specific preparations may help selected patients, especially in certain forms of ulcerative colitis, but results are not consistent for Crohn's disease. |
May support symptom management or remission maintenance in carefully selected cases. |
Low to moderate |
Should not replace prescribed therapy; treatment effects depend heavily on diagnosis, disease activity, and formulation. |
| Probiotics for metabolic inflammation |
Meta-analyses have reported small changes in markers such as C-reactive protein in some adults with metabolic conditions, but findings are heterogeneous. |
May modestly support glucose regulation, lipid profiles, or gut barrier function alongside lifestyle measures. |
Low |
Effects are generally small and are not a substitute for weight management, physical activity, dietary changes, or medical care. |
| Personalized strain selection |
There is currently no universally validated test that reliably identifies one best probiotic for an individual's inflammation. |
Choosing a product based on the target condition, documented strain identity, and clinical evidence may improve decision-making. |
Insufficient evidence |
Microbiome composition, diet, medications, age, and health status can influence response; a trial may produce no benefit. |